Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCTR | P47872 | 9/20 | 0.76 |
| ▸ | SMO | Q99835 | 1/20 | 0.76 |
| ▸ | FLT3 | P36888 | 9/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075703 | 0.89 | SCTR (0.67) | SCTRSMOFLT3PDGFRA | |
| SCHEMBL14075684 | 0.89 | SCTR (0.71) | SCTRSMOFLT3PDGFRA | |
| Purmorphamine SCHEMBL29358352 | 0.86 | SCTR (1.00) | SCTRSMOFLT3PDGFRA | |
| Purmorphamine SCHEMBL1548273 | 0.86 | SCTR (1.00) | SCTRSMOFLT3PDGFRA | |
| SCHEMBL14075696 | 0.85 | SCTR (0.98) | SCTRSMOFLT3PDGFRA | |
| SCHEMBL14075697 | 0.84 | SCTR (0.95) | SCTRSMOFLT3PDGFRA | |
| Naphthalene SCHEMBL28900683 | 0.82 | SCTR (0.66) | SCTRSMOFLT3PDGFRA | |
| SCHEMBL16367807 | 0.80 | SCTR (0.89) | SCTRSMOFLT3PDGFRA | |
| SCHEMBL14075693 | 0.80 | FLT3 (0.67) | SCTRSMOFLT3PDGFRA | |
| SCHEMBL14075691 | 0.79 | SCTR (0.74) | SCTRSMOFLT3PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | SHH, GLI1, SMO | SCTR 4057/4885SMO 3/4885FLT3 2835/4885 |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | SHH, GLI1, SMO | SCTR 4057/4885SMO 3/4885FLT3 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.